The article discusses the concern over the number of deaths (244) and other adverse events linked to nuplazid. The drug was approved in April of 2016 as a much needed treatment for Parkinson's disease psychosis.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,